Johnson & Johnson (JNJ)
J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
The health-products company said it planned to hive off its DePuy Synthes unit to focus on higher-growth areas.
3 Top Dividend Aristocrats To Own Near All-Time Highs
Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting bullish momentum driven by strong results or favorable operating conditions.
Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Johnson & Johnson (JNJ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
Johnson & Johnson NYSE: JNJ MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-model changes and continued investment in differentiated technologies.
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Johnson & Johnson (JNJ) reached $269.12 at the closing of the latest trading day, reflecting a -2.22% change compared to its last close.
Cramer Says It's Time To Buy The Dip on JNJ
On Tuesday morning's Squawk on the Street, Jim Cramer told viewers to step in on a mid-session drop in Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction).
Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?
Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.
3 Dividend Kings Built to Keep Raising Your Income When Rates Rise
Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.
Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
Johnson & Johnson (JNJ) closed at $271.19 in the latest trading session, marking a +2.01% move from the prior day.
Why Procter & Gamble's Quieter Dividend Outpaces Johnson & Johnson's Growth Story
Both Johnson and Johnson and Procter & Gamble just refreshed decades-long dividend streaks, but one company has a corporate event on the horizon that has derailed other legendary payout records before.
